Natera Inc - Company Profile

Powered by

All the data and insights you need on Natera Inc in one report.

$395 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Natera Inc Strategy Report

  • Understand Natera Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Natera Inc: Overview

Select Item

Natera Inc (Natera) develops genetic and cell-free deoxyribonucleic acid (cfDNA) testing solutions. The company’s products include Signatera, a personalized ctDNA (circulating tumor DNA) blood test to assess MRD (molecular residual disease) and its recurrence; Aletra, a tissue-based genomic profiling test to identify genomic alterations and oncology biomarkers in a tumor; Prospera, a transplant rejection test to evaluate the risk of rejection of a transplanted kidney. It also offers Renasight test to detect genetic cause of kidney diseases, Horizon carrier screening test, Panorama non-invasive prenatal screening test, Empower hereditary cancer test, Vistara prenatal single gene screening test, Anora miscarriage test and Spectrum preimplantation genetic test. Natera is headquartered in Austin, Texas, the US.

 Gain a 360-degree view of Natera Inc and make more informed decisions for your business Gain a 360-degree view of Natera Inc and make more informed decisions for your business Find out more
Headquarters United States of America
Address 13011 Mccallen Pass, Building A Suite 100, Austin, Texas, 78753
Website www.natera.com
Telephone 1 650 2499090
No of Employees 2,958
Industry Medical Equipment
Ticker Symbol & Exchange NTRA (NASD)
Revenue (2022) $820.2M 31.1% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ -16.1% (2022 vs 2021)
Market Cap* $7.0B
Net Profit Margin (2022) XYZ 11.4% (2022 vs 2021)
* As of and is in US$
View Natera Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Natera Inc premium industry data and analytics

70+

Medical Clinical Trials

A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

20+

Medical Pipeline Products

A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included.

Products and Services

Products Brands
Signatera: natera
Circulating Tumor DNA Blood Test Signatera
Prospera: Prospera
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Natera Inc portfolio and identify potential areas for collaboration Understand Natera Inc portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Contracts/Agreements In November, the company entered into an agreement with Merck, under the agreement Merck will utilize Natera’s real-world database to advance oncology research.
2023 Others In September, the company announced the use of its personalised and tumour-informed molecular residual disease (MRD) test, Signatera.
2023 Litigation In July, the company filed a lawsuit in the North Carolina Federal District Court against NeoGenomics Labs for infringement of Natera's U.S. Patent Nos. 11,519,035 and 11,530,454 by NeoGenomics’ RaDaR molecular residual disease assay.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Natera Inc Roche Diagnostics International Ltd Exact Sciences Corp Guardant Health Inc Adaptive Biotechnologies Corp
Headquarters United States of America Switzerland United States of America United States of America United States of America
City Austin Rotkreuz Madison Palo Alto Seattle
State/Province Texas Zug Wisconsin California Washington
No. of Employees 2,958 2,600 6,300 1,793 790
Entity Type Public Private Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Matthew Rabinowitz, Ph.D. Chairman Executive Board 2019 50
Steve Chapman Chief Executive Officer; President; Director Executive Board 2019 44
Michael Brophy Chief Financial Officer Senior Management 2017 41
Robert Schueren Chief Operating Officer Senior Management 2019 -
Olesya Anisimova Chief Accounting Officer Senior Management - -
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Gain insight into Natera Inc key executives to enhance your sales strategy Gain insight into Natera Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward